IRRAS (IRRAS.ST)

Executive Summary

IRRAS is a Swedish medical technology company focused on innovative solutions for neurosurgery and neurocritical care. The company develops and commercializes advanced devices for intracranial pressure (ICP) monitoring and cerebrospinal fluid (CSF) management, with its flagship IRRAflow® system offering dynamic CSF drainage and ICP measurement. IRRAS addresses critical unmet needs in the management of traumatic brain injury, subarachnoid hemorrhage, and other neurological conditions. The company is publicly traded on the Stockholm Stock Exchange (IRRAS.ST) and continues to expand its global footprint, targeting both European and U.S. markets through regulatory approvals and strategic partnerships. Recent efforts have centered on commercializing the IRRAflow system, achieving adoption at leading neurosurgical centers, and building a robust clinical evidence base to support wider adoption.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for IRRAflow System Expansion70% success
• Q2 2027Key Clinical Study Results Publication60% success
• Q3 2026Strategic Partnership or Distribution Agreement in the US50% success